

**Jubilant Pharma Holding Inc.**  
**Balance Sheet as at 31 March 2017**

		USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	Notes	As at 31-Mar-17		As at 31-Mar-16		As at 1-Apr-15	
<b>ASSETS</b>							
<b>Non-current assets</b>							
Property, plant and equipment	1	244,806	15,875	206,882	13,705	-	-
Capital work-in-progress	1	23,260	1,509	-	-	-	-
Financial assets							
i. Non-current investments	2	204,943,945	13,290,614	196,343,845	13,007,780	177,443,845	11,090,241
Income tax asset (net)		-	-	544,623	36,081	544,623	34,039
<b>Total non-current assets</b>		<b>205,212,011</b>	<b>13,307,998</b>	<b>197,095,350</b>	<b>13,057,566</b>	<b>177,988,468</b>	<b>11,124,280</b>
<b>Current assets</b>							
Financial assets							
i. Cash and cash equivalents	3	2,378,285	154,232	758,022	50,219	6,865,913	429,120
ii. Other financial assets	4	102,720,177	6,661,403	84,448,456	5,594,710	62,473,877	3,904,617
Other current assets	5	24,539	1,591	12,202	809	-	-
<b>Total current assets</b>		<b>105,123,001</b>	<b>6,817,226</b>	<b>85,218,680</b>	<b>5,645,738</b>	<b>69,339,790</b>	<b>4,333,737</b>
<b>Total assets</b>		<b>310,335,012</b>	<b>20,125,224</b>	<b>282,314,030</b>	<b>18,703,304</b>	<b>247,328,258</b>	<b>15,458,017</b>
<b>EQUITY AND LIABILITIES</b>							
<b>Equity</b>							
Equity share capital	6(a)	246,586,975	11,610,642	245,086,975	11,508,521	213,486,975	9,466,116
Other equity	6(b)	9,687,965	5,008,787	(227,652)	4,713,410	(5,327,266)	3,543,867
<b>Total equity</b>		<b>256,274,940</b>	<b>16,619,429</b>	<b>244,859,323</b>	<b>16,221,931</b>	<b>208,159,709</b>	<b>13,009,983</b>
<b>LIABILITIES</b>							
<b>Current liabilities</b>							
Financial liabilities							
i. Short-term borrowings		52,087,500	3,377,874	34,100,000	2,259,125	37,750,000	2,359,375
ii. Trade payables	7	594,916	38,580	1,234,305	81,771	1,041,374	65,085
iii. Other financial liabilities	8	1,148,317	74,468	1,969,541	130,483	377,175	23,574
Provisions	9	229,339	14,873	150,861	9,994	-	-
<b>Total current liabilities</b>		<b>54,060,072</b>	<b>3,505,795</b>	<b>37,454,707</b>	<b>2,481,373</b>	<b>39,168,549</b>	<b>2,448,034</b>
<b>Total liabilities</b>		<b>54,060,072</b>	<b>3,505,795</b>	<b>37,454,707</b>	<b>2,481,373</b>	<b>39,168,549</b>	<b>2,448,034</b>
<b>Total equity and liabilities</b>		<b>310,335,012</b>	<b>20,125,224</b>	<b>282,314,030</b>	<b>18,703,304</b>	<b>247,328,258</b>	<b>15,458,017</b>

**PRAKASH C BISHT**  
**CFO (LSI) & Sr. VP (Group Accounts)**

Place: Noida  
Date: 27 April, 2017

**Jubilant Pharma Holding Inc.****Statement of Profit and Loss For the year ended 31 March 2017**

		USD	(₹ in thousand)	USD	(₹ in thousand)
	Notes	For the year ended 31-Mar-17		For the year ended 31-Mar-16	
Revenue from operations					
Other operating revenue	10	397,162	15,615	2,582,332	167,403
Other income	11	236,298	26,657	3,463	227
<b>Total income</b>		<b>633,460</b>	<b>42,272</b>	<b>2,585,795</b>	<b>167,630</b>
<b>Expenses</b>					
Finance costs	12	1,267,199	85,065	1,010,027	65,972
Depreciation and amortization expense	13	24,993	1,677	10,667	719
Other expenses	14	1,747,466	117,195	642,837	42,303
<b>Total expenses</b>		<b>3,039,658</b>	<b>203,937</b>	<b>1,663,531</b>	<b>108,994</b>
<b>(Loss)/profit before tax</b>		<b>(2,406,198)</b>	<b>(161,665)</b>	<b>922,264</b>	<b>58,636</b>
Tax expense					
- Current tax		21,626	1,454	38,316	2,536
- Deferred tax (credit)/charge		(434,672)	(29,243)	426,121	27,255
<b>Total tax expense</b>		<b>(413,046)</b>	<b>(27,789)</b>	<b>464,437</b>	<b>29,791</b>
<b>(Loss)/profit for the year</b>		<b>(1,993,152)</b>	<b>(133,876)</b>	<b>457,827</b>	<b>28,845</b>
<b>Other comprehensive income</b>					
Items that will be reclassified to profit or loss					
Exchange differences on translation of foreign operations		-	(369,349)	-	837,961
<b>Other comprehensive income for the year, net of tax</b>		<b>-</b>	<b>(369,349)</b>	<b>-</b>	<b>837,961</b>
<b>Total comprehensive income for the year</b>		<b>(1,993,152)</b>	<b>(503,225)</b>	<b>457,827</b>	<b>866,806</b>

**PRAKASH C BISHT****CFO (LSI) & Sr. VP (Group Accounts)**

Place: Noida

Date: 27 April, 2017

**Jubilant Pharma Holding Inc.**  
**Statement of Cash Flows For the year ended 31 March 2017**

	USD (₹ in thousand)		USD (₹ in thousand)	
	For the year ended 31-Mar-17		For the year ended 31-Mar-16	
<b>A. Cash flow from operating activities</b>				
Net (loss)/profit before tax	(2,406,198)	(161,665)	922,264	58,636
Adjustments :				
Depreciation and amortisation expense	24,993	1,677	10,667	719
Finance costs	1,267,199	85,065	1,010,027	65,972
Provision for diminution in the value of investment	1,400,000	93,884	400,000	26,088
Interest income	(397,162)	(26,657)	(3,463)	(227)
	<b>2,295,030</b>	<b>153,969</b>	<b>1,417,231</b>	<b>92,552</b>
<b>Operating cash flow before working capital changes</b>	<b>(111,168)</b>	<b>(7,696)</b>	<b>2,339,495</b>	<b>151,188</b>
Increase in trade and other receivables	(26,608,190)	(1,784,345)	(13,393,958)	(873,554)
Increase in investments	(1,400,000)	(93,884)	(27,900,000)	(1,819,638)
(Decrease)/increase in trade payables, provisions and other liabilities	(514,615)	(34,510)	5,003,772	326,346
<b>Cash generated from operations</b>	<b>(28,633,973)</b>	<b>(1,920,435)</b>	<b>(33,950,691)</b>	<b>(2,215,658)</b>
Income tax and wealth tax paid (net of refund)	12,866,438	862,823	377,350	24,611
Interest received	121,294	8,134	3,463	227
<b>Net cash generated from operating activities</b>	<b>(15,646,241)</b>	<b>(1,049,478)</b>	<b>(33,569,878)</b>	<b>(2,190,820)</b>
<b>B. Cash flow from investing activities</b>				
Purchase of fixed assets/ capital advances	(86,177)	(5,779)	(217,549)	(14,656)
<b>Net cash used in investing activities</b>	<b>(86,177)</b>	<b>(5,779)</b>	<b>(217,549)</b>	<b>(14,656)</b>
<b>C. Cash flow arising from financing activities</b>				
Proceeds from issues of equity shares	1,500,000	102,121	31,600,000	2,042,405
Proceeds/(repayments) of short term borrowings - with in group	17,987,500	1,206,242	(3,650,000)	(238,053)
Finance costs paid	(2,134,819)	(143,161)	(270,464)	(17,640)
<b>Net cash used in financing activities</b>	<b>17,352,681</b>	<b>1,165,202</b>	<b>27,679,536</b>	<b>1,786,712</b>
<b>D. Effect of exchange rate changes</b>	-	(5,932)	-	39,863
<b>Net decrease in cash and cash equivalents (A+B+C+D)</b>	<b>1,620,263</b>	<b>104,013</b>	<b>(6,107,891)</b>	<b>(378,901)</b>
Add: cash and cash equivalents at the beginning of year	758,022	50,219	6,865,913	429,120
<b>Cash and cash equivalents at the end of the year</b>	<b>2,378,285</b>	<b>154,232</b>	<b>758,022</b>	<b>50,219</b>

**PRAKASH C BISHT**  
**CFO (LSI) & Sr. VP (Group Accounts)**

Place: Noida  
Date: 27 April, 2017

**Jubilant Pharma Holding Inc.**

Notes to the financial statements for the year ended 31 March 2017

**1 : Property, Plant and equipment****(USD)**

<b>Description</b>	<b>Furniture &amp; fixtures</b>	<b>Office Equipment</b>	<b>Total</b>
<b>Deemed cost as at 1 April 2015</b>	-	-	-
Additions during the year	92,594	124,955	217,549
<b>Gross carrying amount as at 31 March 2016</b>	<b>92,594</b>	<b>124,955</b>	<b>217,549</b>
<b>Accumulated depreciation as at 1 April 2015</b>	-	-	-
Depreciation charge for the year	4,617	6,050	10,667
<b>Accumulated depreciation as at 31 March 2016</b>	<b>4,617</b>	<b>6,050</b>	<b>10,667</b>
<b>Net carrying amount as at 31 March 2016</b>	<b>87,977</b>	<b>118,905</b>	<b>206,882</b>
<b>Net carrying amount as at 1 April 2015</b>	-	-	-
<b>Capital work in progress</b>			
As at 1 April 2015			-
As at 31 March 2016			-

<b>Description</b>	<b>Furniture &amp; fixtures</b>	<b>Office Equipment</b>	<b>Total</b>
<b>Gross carrying amount as at 1 April 2016</b>	92,594	124,955	217,549
Additions during the year	53,647	9,271	62,918
<b>Gross carrying amount as at 31 March 2017</b>	<b>146,241</b>	<b>134,226</b>	<b>280,467</b>
<b>Accumulated depreciation as at 1 April 2016</b>	4,617	6,050	10,667
Depreciation charge for the year	12,144	12,850	24,994
<b>Accumulated depreciation as at 31 March 2017</b>	<b>16,761</b>	<b>18,900</b>	<b>35,661</b>
<b>Net carrying amount as at 31 March 2017</b>	<b>129,480</b>	<b>115,326</b>	<b>244,806</b>
<b>Net carrying amount as at 1 April 2016</b>	<b>87,977</b>	<b>118,905</b>	<b>206,882</b>
<b>Capital work in progress</b>			
As at 31 March 2016			-
As at 31 March 2017			23,260

**Jubilant Pharma Holding Inc.**

Notes to the financial statements for the year ended 31 March 2017

**1 : Property, Plant and equipment**

(₹ in thousand)

Description	Furniture & fixtures	Office Equipment	Total
<b>Deemed cost as at 1 April 2015</b>	-	-	-
Additions during the year	6,238	8,418	14,656
Deductions during the year	-	-	-
Currency translation adjustment	(104)	(140)	(244)
<b>Gross carrying amount as at 31 March 2016</b>	<b>6,134</b>	<b>8,278</b>	<b>14,412</b>
<b>Accumulated depreciation as at 1 April 2015</b>	-	-	-
Depreciation charge for the year	311	408	719
Deductions during the year	-	-	-
Currency translation adjustment	(5)	(7)	(12)
<b>Accumulated depreciation as at 31 March 2016</b>	<b>306</b>	<b>401</b>	<b>707</b>
<b>Net carrying amount as at 31 March 2016</b>	<b>5,828</b>	<b>7,877</b>	<b>13,705</b>
<b>Net carrying amount as at 1 April 2015</b>	-	-	-
<b>Capital work in progress</b>			
As at 1 April 2015	-	-	-
As at 31 March 2016	-	-	-

Description	Furniture & fixtures	Office Equipment	Total
<b>Gross carrying amount as at 1 April 2016</b>	6,134	8,278	14,412
Additions during the year	3,596	622	4,218
Currency translation adjustment	(246)	(195)	(441)
<b>Gross carrying amount as at 31 March 2017</b>	<b>9,484</b>	<b>8,705</b>	<b>18,189</b>
<b>Accumulated depreciation as at 1 April 2016</b>	306	401	707
Depreciation charge for the year	815	862	1,677
Currency translation adjustment	(34)	(36)	(70)
<b>Accumulated depreciation as at 31 March 2017</b>	<b>1,087</b>	<b>1,227</b>	<b>2,314</b>
<b>Net carrying amount as at 31 March 2017</b>	<b>8,397</b>	<b>7,478</b>	<b>15,875</b>
<b>Net carrying amount as at 1 April 2016</b>	<b>5,828</b>	<b>7,877</b>	<b>13,705</b>
<b>Capital work in progress</b>			
As at 31 March 2016	-	-	-
As at 31 March 2017	-	-	1,509

**Jubilant Pharma Holding Inc.**

Notes to the financial statements for the year ended 31 March 2017

**2. Non-current investments (At Cost)**

	USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
	Non-current		Non-current		Non-current	
<b>Trade investments</b>						
<b>Investment in equity instruments (fully paid up equity shares)</b>						
Jubilant Clinsys Inc.	-	-	-	-	-	-
40,562,584 shares (31 March 2016: 39,797,557 shares and 01 April 2015: 39,578,978 shares) of zero par value						
HSL Holdings Inc.	138,285,000	8,967,782	129,685,000	8,591,631	110,785,000	6,924,063
1,959 shares (31 March 2016: 1,853 shares 01 April 2015: 1,583 shares) @ USD 0.01 par value						
Cadista Holdings Inc.	66,658,745	4,322,820	66,658,745	4,416,142	66,658,745	4,166,172
117,797,190 shares (31 March 2016: 117,797,190 shares 01 April 2015: 117,797,190 shares) @ USD 0.001 par value						
Jubilant Pharma Trading Inc.	100	6	100	7	100	6
101 shares (31 March 2016: 101 shares 01 April 2015: 101 shares) of zero par value						
Jubilant Draximage Radiopharmacies Inc.	100	6	-	-	-	-
100 shares of zero par value						
<b>Total</b>	<b>204,943,945</b>	<b>13,290,614</b>	<b>196,343,845</b>	<b>13,007,780</b>	<b>177,443,845</b>	<b>11,090,241</b>

**3. Cash and cash equivalents**

	USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
<b>Balances with banks</b>						
- in current accounts	2,378,285	154,232	758,022	50,219	6,865,913	429,120
Cash on hand	-	-	-	-	-	-
<b>Total cash and cash equivalents</b>	<b>2,378,285</b>	<b>154,232</b>	<b>758,022</b>	<b>50,219</b>	<b>6,865,913</b>	<b>429,120</b>

**4. Other financial assets**

	USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
	Current		Current		Current	
Loans to related parties	96,993,500	6,290,028	71,616,000	4,744,560	61,816,000	3,863,500
Advances recoverable from related parties	5,726,677	371,375	12,832,456	850,150	657,877	41,117
<b>Total loans</b>	<b>102,720,177</b>	<b>6,661,403</b>	<b>84,448,456</b>	<b>5,594,710</b>	<b>62,473,877</b>	<b>3,904,617</b>

**5. Other current assets**

	USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
Prepayments	-	-	9,702	643	-	-
Loans and advances to employees	24,539	1,591	2,500	166	-	-
<b>Total other current assets</b>	<b>24,539</b>	<b>1,591</b>	<b>12,202</b>	<b>809</b>	<b>-</b>	<b>-</b>

**Jubilant Pharma Holding Inc.**

Notes to the financial statements for the year ended 31 March 2017

**7. Trade payables**

	USD (₹ in thousand)		USD (₹ in thousand)		USD (₹ in thousand)	
	As at		As at		As at	
	31 March 2017	31 March 2016	31 March 2016	31 March 2016	01 April 2015	01 April 2015
<b>Current</b>						
Trade payables	594,916	38,580	1,234,305	81,771	1,041,374	65,085
<b>Total trade payables</b>	<b>594,916</b>	<b>38,580</b>	<b>1,234,305</b>	<b>81,771</b>	<b>1,041,374</b>	<b>65,085</b>

**8. Other financial liabilities**

	USD (₹ in thousand)		USD (₹ in thousand)		USD (₹ in thousand)	
	As at		As at		As at	
	31 March 2017	31 March 2016	31 March 2016	31 March 2016	01 April 2015	01 April 2015
<b>Current</b>						
Interest accrued but not due on borrowings	216,384	14,033	1,084,004	71,815	344,441	21,528
Employee benefit payable	931,933	60,435	885,537	58,668	32,734	2,046
<b>Total other current financial liabilities</b>	<b>1,148,317</b>	<b>74,468</b>	<b>1,969,541</b>	<b>130,483</b>	<b>377,175</b>	<b>23,574</b>

**Jubilant Pharma Holding Inc.**

Notes to the financial statements for the year ended 31 March 2017

**9. Provisions**

USD

	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
	Current	Non-current	Current	Non-current	Current	Non-current
Provisions for employee benefits	229,339	-	150,861	-	-	-
<b>Total provisions</b>	<b>229,339</b>	<b>-</b>	<b>150,861</b>	<b>-</b>	<b>-</b>	<b>-</b>

**9. Provisions**

(₹ in thousand)

	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
	Current	Non-current	Current	Non-current	Current	Non-current
Provisions for employee benefits	14,873	-	9,994	-	-	-
<b>Total provisions</b>	<b>14,873</b>	<b>-</b>	<b>9,994</b>	<b>-</b>	<b>-</b>	<b>-</b>



**Jubilant Pharma Holding Inc.**

Notes to the financial statements for the year ended 31 March 2017

**6 (a) Equity share capital**

	USD		USD		USD	
	(₹ in thousand)		(₹ in thousand)		(₹ in thousand)	
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
<b>Authorised</b>						
Equity share capital						
3,000 shares at zero par value	-	-	-	-	-	-
(31 March 2016 and 01 April 2015 - 3000 shares at zero par value)						
	-	-	-	-	-	-
<b>Issued, Subscribed and Paid up</b>						
Equity share capital						
200 shares (31 March 2016 and 01 April 2015 200 shares) of class A and 1089 shares (31 March 2016: 1081 shares and 01 April 2015: 911 shares) of class B common stock	246,586,975	11,610,642	245,086,975	11,508,522	213,486,975	9,466,116
	<b>246,586,975</b>	<b>11,610,642</b>	<b>245,086,975</b>	<b>11,508,522</b>	<b>213,486,975</b>	<b>9,466,116</b>

**Movements in equity share capital**

	No. of shares	(₹ in thousand)	No. of shares	(₹ in thousand)	No. of shares	(₹ in thousand)
At the commencement of the year	1,281	11,508,522	1,111	9,466,116	1,111	9,466,116
Additions during the year	8	102,120	170	2,042,406	-	-
At the end of the year	1,289	11,610,642	1,281	11,508,522	1,111	9,466,116

**Terms and rights attached to equity shares**

The Company has two classes of stock, Class A common stock and Class B common stock. The total number of shares of all classes of stock which the Company is authorized to issue is 3,000 shares of zero par value. Of the total authorized shares, 1,500 shares shall be authorized to be issued as Class A common stock, at zero par value and 1,500 shares shall be authorized to be issued as Class B common stock, at zero par value.

The voting powers for the shareholder shall be vested equally in the holders of Class A common stock and Class B common stock, with each share of stock entitled to one vote. No rights to class voting shall exist for either class of common stock.

The holder of Class A common stock shall have all rights and preferences with respect to dividend declared by the Company, except to the extent that the Board of Directors makes a special dividend declaration to the holders of Class B common stock.

Except for the foregoing dividend preference rights, Class A common stock and Class B common stock shall have equal rights with respect to (i) voting; (ii) liquidating distributions made to the shareholders; (iii) any distribution of the Company assets to its shareholders; and (iv) any other shareholder rights and privileges.

In the event of liquidation of the Company, the holders of equity shares shall be entitled to receive all of the remaining assets of the Company, after distribution of all preferential amounts, if any. Such amounts will be in proportion to the number of equity shares held by the stockholders.

**Details of shareholders holding more than 5% shares in the company**

	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
	No. of shares	% holding	No. of shares	% holding	No. of shares	% holding
Jubilant Pharma Limited, Singapore - the holding company	1,089	84.48%	1,081	84.39%	911	82%
Class B common stock at zero par value						
Jubilant Generics Limited, India	200	15.52%	200	15.61%	200	18%
<b>Class A common stock at zero par value</b>						

**6 (b) Other Equity**

	USD		
	Reserves and Surplus		
	Capital reserve	Retained earnings	Total
<b>As at 1 April 2015</b>	<b>64,546,179</b>	<b>(69,873,445)</b>	<b>(5,327,266)</b>
Profit for the year	-	457,827	457,827
Additions during the year	4,641,787	-	4,641,787
<b>Total comprehensive income for the year</b>	<b>4,641,787</b>	<b>457,827</b>	<b>5,099,614</b>
			-
<b>As at 31 March 2016</b>	<b>69,187,966</b>	<b>(69,415,618)</b>	<b>(227,652)</b>

	USD		
	Reserves and Surplus		
	Capital reserve	Retained earnings	Total
<b>As at 1 April 2016</b>	<b>69,187,966</b>	<b>(69,415,618)</b>	<b>(227,652)</b>
Profit for the year	-	(1,993,152)	(1,993,152)
Additions during the year	11,908,769	-	11,908,769
<b>Total comprehensive income for the year</b>	<b>11,908,769</b>	<b>(1,993,152)</b>	<b>9,915,617</b>
<b>As at 31 March 2017</b>	<b>81,096,735</b>	<b>(71,408,770)</b>	<b>9,687,965</b>

**Jubilant Pharma Holding Inc.**

Notes to the financial statements for the year ended 31 March 2017

(₹ in thousand)

	Reserves and Surplus		Other comprehensive income	Total
	Capital reserve	Retained earnings	Foreign currency translation reserve	
	<b>As at 1 April 2015</b>	<b>3,800,292</b>	<b>(256,425)</b>	
Profit for the year	-	28,845	-	28,845
Additions during the year	302,737	-	837,961	1,140,698
<b>Total comprehensive income for the year</b>	<b>302,737</b>	<b>28,845</b>	<b>837,961</b>	<b>1,169,543</b>
<b>As at 31 March 2016</b>	<b>4,103,029</b>	<b>(227,580)</b>	<b>837,961</b>	<b>4,713,410</b>

	Reserves and Surplus		Other comprehensive income	Total
	Capital reserve	Retained earnings	Foreign currency translation reserve	
	<b>As at 1 April 2016</b>	<b>4,103,029</b>	<b>(227,580)</b>	
Profit for the year	-	(133,876)	-	(133,876)
Additions during the year	798,602	-	(369,349)	429,253
<b>Total comprehensive income for the year</b>	<b>798,602</b>	<b>(133,876)</b>	<b>(369,349)</b>	<b>295,377</b>
<b>As at 31 March 2017</b>	<b>4,901,631</b>	<b>(361,456)</b>	<b>468,612</b>	<b>5,008,787</b>

**Jubilant Pharma Holding Inc.**

Notes to the financial statements for the year ended 31 March 2017

**10. OTHER OPERATING INCOME**

Particulars	USD (₹ in thousand)		USD (₹ in thousand)	
	For the year ended		For the year ended	
	31 March 2017		31 March 2016	
Interest Income	397,162	26,657	3,463	227
<b>Total other operating income</b>	<b>397,162</b>	<b>26,657</b>	<b>3,463</b>	<b>227</b>

**11. OTHER INCOME**

Particulars	USD (₹ in thousand)		USD (₹ in thousand)	
	For the year ended		For the year ended	
	31 March 2017		31 March 2016	
Other non-operating income	236,298	15,615	2,582,332	167,403
<b>Total other non-operating income</b>	<b>236,298</b>	<b>15,615</b>	<b>2,582,332</b>	<b>167,403</b>

**12. Finance costs**

Particulars	USD (₹ in thousand)		USD (₹ in thousand)	
	For the year ended		For the year ended	
	31 March 2017		31 March 2016	
Interest and finance charges on financial liabilities not at fair value through profit or loss	1,267,199	85,065	1,010,027	65,972
Other borrowings cost	-	-	-	-
<b>Finance costs expensed in profit or loss</b>	<b>1,267,199</b>	<b>85,065</b>	<b>1,010,027</b>	<b>65,972</b>

**13. Depreciation and amortization expenses**

Particulars	USD (₹ in thousand)		USD (₹ in thousand)	
	For the year ended		For the year ended	
	31 March 2017		31 March 2016	
Depreciation of property, plant and equipment	24,993	1,677	10,667	719
<b>Total depreciation and amortisation expense</b>	<b>24,993</b>	<b>1,677</b>	<b>10,667</b>	<b>719</b>

**14. Other expenses**

Particulars	USD (₹ in thousand)		USD (₹ in thousand)	
	For the year ended		For the year ended	
	31 March 2017		31 March 2016	
Rates and taxes	5,426	364	7,896	481
Payments to auditors	8,600	577	17,135	1,122
Legal and professional fees	326,778	21,927	245,843	16,374
Bank charges	5,618	377	2,756	181
Foreign Exchange Gain/Loss	1,044	66	(30,793)	(1,943)
Diminution in value of investment	1,400,000	93,884	400,000	26,088
<b>Total other expenses</b>	<b>1,747,466</b>	<b>117,195</b>	<b>642,837</b>	<b>42,303</b>